"
Team:Lethbridge/human practices
From 2014.igem.org
| Line 46: | Line 46: | ||
<br> | <br> | ||
<br> | <br> | ||
| + | |||
| + | <h2>Ethics & Human Practice</h2> | ||
| + | |||
| + | <p>In an effort to conduct our research in an ethically responsible manner, we are utilizing tissue cultures rather than live animals for our initial tests (in accordance with the 3Rs principle defined by the Canadian Council on Animal Care). Additionally, we have collaborated with the Public Health Agency of Canada (PHAC) and health care professionals to evaluate current legislation and sentiments regarding cell and genetic therapies.</p> | ||
| + | |||
| + | <p>With regards to human practice, because microglia can be derived directly from patient bone marrow cells, this study has the potential to provide a method of personalized, non-immunogenic neural rehabilitation [16]. In addition, we are also addressing the growing prevalence of bacterial antibiotic resistance around the globe [17]. Our antibiotic-free plasmid selection system will help curb the spread of antibiotic resistance by reducing the potential for horizontal gene transfer of antibiotic resistance from lab strains to wild bacterial strains and by reducing the amount of antibiotics in lab waste and thus decreasing selective pressure towards antibiotic resistance. </p> | ||
| + | |||
| + | <h2>References</h2> | ||
Revision as of 05:09, 17 October 2014
|
|
|
|
|
|
|
|
|
|
|---|
Policy and Practice
Dr. Toni Winder.
Neurologist.
Lethbridge, Alberta.
An interview with Dr. Winder discussing brain injury and the effects it has on patients
Dr. Randall Barley.
Ph.D. Experimental Surgery.
Lethbridge, Alberta.
An interview with Dr. Barley discussing cell therapies and genetic engineering
Ethics & Human Practice
In an effort to conduct our research in an ethically responsible manner, we are utilizing tissue cultures rather than live animals for our initial tests (in accordance with the 3Rs principle defined by the Canadian Council on Animal Care). Additionally, we have collaborated with the Public Health Agency of Canada (PHAC) and health care professionals to evaluate current legislation and sentiments regarding cell and genetic therapies.
With regards to human practice, because microglia can be derived directly from patient bone marrow cells, this study has the potential to provide a method of personalized, non-immunogenic neural rehabilitation [16]. In addition, we are also addressing the growing prevalence of bacterial antibiotic resistance around the globe [17]. Our antibiotic-free plasmid selection system will help curb the spread of antibiotic resistance by reducing the potential for horizontal gene transfer of antibiotic resistance from lab strains to wild bacterial strains and by reducing the amount of antibiotics in lab waste and thus decreasing selective pressure towards antibiotic resistance.
References
